What is Supha Pharmachem Ltd (539561) share price return in the past 10 years?

Data is not available for this company

What is the share price of Supha Pharmachem Ltd (539561)?

Company share prices are keep on changing according to the market conditions. The current trading price of Supha Pharmachem Ltd (539561) on 11-Jun-2026 16:59:59 at 16:59 is 0.29.

What is the P/E ratio of Supha Pharmachem?

The latest standalone P/E ratio of Supha Pharmachem as of 11-Jun-2026 is 0.00.

What is the P/B ratio of Supha Pharmachem Ltd (539561)?

The latest standalone P/B ratio of Supha Pharmachem Ltd (539561) as of 11-Jun-2026 is 0.29.

What is the 52-week high and low of Supha Pharmachem Ltd (539561)?

The 52-week high of Supha Pharmachem Ltd (539561) is Rs. 1.80 and the 52-week low is Rs. 0.30.

Supha Pharmachem Ltd (539561) Share Analysis – Quality, Valuation Zone & Price Trend & DeciZen Rating

Name: Supha Pharmachem Ltd (539561)
Brand: Supha Pharmachem

Supha Pharmachem Ltd (539561)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 539561 NSE: Trading | Small Cap | Supha Pharmachem Share Price

Supha Pharmachem Ltd (539561)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 539561 NSE: Trading | Small Cap | Supha Pharmachem Share Price

Key Metrics

Valuation Multiples

Market Cap

₹26 Cr.

Current Price

₹0.3

52-Week Low / High

₹0 / 2

TTM EPS

₹-0

TTM Sales

₹147 Cr.

Book Value per Share

₹1

P/E Ratio

0.00

Lower than its 5-year historical median

Industry PE

35.7

Price to Book (P/B)

0.29

Lower than its 5-year historical median

Price to Sales (P/S)

0.18

Lower than its 5-year historical median

EV/EBITDA

1151.91

Higher than its 5-year historical median

Dividend Yield

0.00%

Profitability Efficiency

Return on Equity (ROE)

3.55%

Outperforms industry median

Return on Capital Employed (ROCE)

1.76%

Underperforms industry median

Return on Assets (ROA)

0.09%

Operating Profit Margin

0.2%

Net Profit Margin

0.69%

Gross Profit Margin

1.7%

Growth Momentum
1-yr vs 3-yr growth

Sales Growth (1 Year)

Slowing versus 3-year growth rate

-94.49%

Operating Profit Growth (1 Year)

Slowing versus 3-year growth rate

-98.42%

Net Profit Growth (1 Year)

Slowing versus 3-year growth rate

-95.33%

Asset Quality

Promoter Holding

1.13%

Pledged shares (%) of Promoter's holding (%)

0.00%

Reserves

₹3 Cr.

Equity

₹88.2 Cr.

Face Value

₹1

All Time Low / High

₹0.07 / 31.35

Supha Pharmachem stock performance

Key Ratios

Check Before You Invest

M-Cap below 100cr DeciZen not available

Q.1 Is Supha Pharmachem Ltd a good quality company?

Supha Pharmachem Ltd is a quality company, based on a multi-year financial track record.

This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

We have analysed the performance of the company on the following:

How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.

How does Supha Pharmachem Ltd performance compare with that of its Peers?

Q.1 Revenue growth of Supha Pharmachem Ltd vs industry peers?

Supha Pharmachem Ltd revenue CAGR is 138.39%, compared to the industry median CAGR of 0%, indicating faster growth and gaining its market share.

Q.1 Promoter shareholding and pledge status of Supha Pharmachem Ltd?

Promoters hold 1.13% of the Supha Pharmachem Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Q.1 Stock return of Supha Pharmachem Ltd over the last decade?

Over the last 5 year(s), the stock has delivered a CAGR of -6.51% based on the current price.

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
ROCE % ⓘ	0.7%	0.1%	0.6%	0.6%	11.2%	7.4%	18.2%	102.5%	99.5%	1.8%	-
Value Creation Index ⓘ	-1.0	-1.0	-1.0	-1.0	-0.2	-0.5	0.3	6.3	6.1	-0.9	-
Growth Parameters ⓘ
Sales ⓘ	3.9	1.3	0.4	0.2	2.9	90	505	510	4,042	223	147
Sales YoY Gr.	-	-66.2%	-73.7%	-54.3%	1,706.3%	3,015.2%	460.7%	1%	692.7%	-94.5%	-
Adj EPS ⓘ	0	0	0	0	0	0	0	0.1	0.3	-0.1	-0
YoY Gr.	-	NA	NA	NA	NA	NA	100%	300%	287.5%	-132.3%	-
BVPS (₹) ⓘ	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.2	0.7	0.8	1
Adj Net Profit ⓘ	0	0	0	0	0.3	0.5	1.1	4.9	18	-5.9	-2
Cash Flow from Ops. ⓘ	-1.4	0.1	-0.2	-0.1	-0.2	-10.2	11.3	20.5	-74.2	-1,079	-
Debt/CF from Ops. ⓘ	-0	0	0	-1.1	-1.8	-1	0	0	-0.8	-1.1	-

CAGR ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	56.6%	138.4%	-23.9%	-94.5%
Adj EPS ⓘ	NA	NA	-271%	-132.3%
BVPSⓘ	35.1%	65.7%	102.7%	1.4%
Share Price	-	-14.4%	-73.5%	-75.6%

Key Financial Parameters ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
Return on Equity % ⓘ	0.3	0.1	0.5	0.2	8.4	13.3	24.5	63.4	67.7	-13.8	-2.3
Op. Profit Mgn % ⓘ	-7.6	-7.4	0.2	-43.2	13.4	0.8	0.4	1.4	0.9	0.2	-9.4
Net Profit Mgn % ⓘ	0.2	0.3	3.9	3.9	9.4	0.5	0.2	1	0.5	-2.7	-1.2
Debt to Equity ⓘ	0	0	0	0	0.1	2.7	0	0	1.3	26.4	12
Working Cap Days ⓘ	415	1,050	3,243	6,366	351	82	94	485	139	2,858	4,398
Cash Conv. Cycle ⓘ	325	801	2,189	2,045	110	10	17	27	21	1,038	3,071

Profit And Loss

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Sales	3.93	1.33	0.35	0.16	2.89	90.03	504.79	509.84	4,041.71	222.50
Operating Expenses ⓘ +	4.23	1.43	0.35	0.23	2.50	89.31	502.98	502.67	4,007.51	221.96
Manufacturing Costs	0.59	0.79	0.02	0.01	0.13	0.21	1.74	1.74	1.01	1.42
Material Costs	3.39	0.46	0.14	0.05	1.67	87.74	498.47	493.86	4,001.38	216.11
Employee Cost	0.05	0.04	0.13	0.04	0.18	0.19	0.21	0.55	0.40	0.41
Other Costs ⓘ	0.21	0.14	0.06	0.13	0.52	1.17	2.56	6.52	4.72	4.02
Operating Profit ⓘ	-0.30	-0.10	0	-0.07	0.39	0.72	1.82	7.17	34.19	0.54
Operating Profit Margin (%)	-7.6%	-7.4%	0.2%	-43.2%	13.4%	0.8%	0.4%	1.4%	0.8%	0.2%
Other Income ⓘ +	0.33	0.10	0.02	0.09	0.01	0.01	0.01	0.83	21.10	10.80
Exceptional Items ⓘ	0	0	0	0	0	0	0	0	0	0
Interest ⓘ	0.01	0	0	0	0.01	0.02	0.23	0.45	4.78	7.64
Depreciation ⓘ	0.01	0	0	0	0.01	0.06	0.07	0.15	0.06	0.04
Profit Before Tax ⓘ	0.01	0	0.02	0.02	0.38	0.65	1.53	7.40	50.45	3.66
Tax ⓘ	0	0	0	0.01	0.10	0.17	0.45	1.97	17.72	2.13
Profit After Tax	0.01	0	0.01	0.01	0.28	0.48	1.08	5.43	32.73	1.53
PAT Margin (%)	0.3%	0.3%	3.9%	5.0%	9.6%	0.5%	0.2%	1.1%	0.8%	0.7%
Adjusted EPS (₹)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.6	0.0
Dividend Payout Ratio (%)	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%

Valuation of Supha Pharmachem - Standalone

YTD 1Y 3Y 5Y 10Y Max

Analyst's Notes

No data found!

Balance Sheet

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Equity and Liabilities
Shareholders Fund +	3.04	3.04	3.07	3.08	3.35	3.86	4.94	10.36	42.96	43.30
Share Capital ⓘ	3.60	3.60	3.60	3.60	3.60	3.60	3.60	3.60	10.08	40.32
Reserves ⓘ	-0.56	-0.56	-0.53	-0.52	-0.25	0.26	1.34	6.76	32.88	2.98
Debt +	0	0	0	0.08	0.36	10.50	0	0	57.70	1,141.39
Long Term Debt	0	0	0	0.08	0.36	10.50	0	0	0	0
Short Term Debt	0	0	0	0	0	0	0	0	57.70	1,141.39
Minority Interest	0	0	0	0	0	0	0	0	0	0
Trade Payables	1.37	0	0	0.35	0.39	23.77	124.56	84.22	712.29	320.98
Others Liabilities ⓘ	0.16	0.25	0.06	0.02	0.16	0.40	94.26	1,059.63	1,134.95	33.94
Total Liabilities ⓘ	4.57	3.29	3.13	3.53	4.27	38.53	223.76	1,154.22	1,947.90	1,539.61
Fixed Assets
Net Fixed Assets ⓘ +	0.02	0.01	0.01	0	0.23	0.21	0.19	0.08	0.05	0.01
Gross Block	0.21	0.21	0.21	0	0.24	0.29	0.34	0.20	0.22	0.22
Accumulated Depreciation	0.19	0.19	0.20	0	0.01	0.08	0.15	0.12	0.18	0.22
CWIP ⓘ	0	0	0	0	0	0	0	0	0	0
Investments ⓘ	0	0	0	0	0	0	0	0	0	0.07
Inventories	0.83	0	0	0.20	0.70	3.11	83.87	7.32	133.23	269.38
Trade Receivables	2.85	2.17	2.03	0.14	1.50	23.68	64	172.37	920.60	590.92
Cash Equivalents	0.01	0.16	0.02	1.08	0.93	0.81	1.44	21.86	1.52	1.36
Others Assets ⓘ	0.86	0.95	1.07	2.11	0.91	10.72	74.27	952.59	892.49	677.88
Total Assets ⓘ	4.57	3.29	3.13	3.53	4.27	38.53	223.76	1,154.22	1,947.90	1,539.61

Cash Flow

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Cash Flow From Operating Activity ⓘ +	-1.36	0.07	-0.16	-0.07	-0.20	-10.21	11.28	20.50	-74.16	-1,078.63
PBT ⓘ	0.01	0	0.02	0.01	0.38	0.65	1.53	7.40	50.45	3.66
Adjustment ⓘ	-0.05	-0.09	0	-0.09	0.01	0.06	0.18	0.19	3.84	5.20
Changes in Working Capital ⓘ	-1.32	0.15	-0.17	0	-0.59	-10.89	10.03	14.89	-110.64	-1087
Tax Paid ⓘ	-0	-0	-0	0.01	0	-0.04	-0.45	-1.98	-17.81	-0.49
Cash Flow From Investing Activity ⓘ +	1.48	0.09	0.02	1.06	-0.24	-0.04	-0.05	-0.04	0.09	0.06
Capex	1.41	0	0	0.02	-0.24	-0.04	-0.05	-0.04	0	0
Net Investments	0	0	0	0	0	0	0	0	0	0
Others ⓘ	0.07	0.09	0.02	1.04	0	0	0	0	0.09	0.06
Cash Flow From Financing Activity ⓘ +	-0.11	-0	-0	0.08	0.29	10.14	-10.61	-0.04	53.74	1,078.40
Net Proceeds from Shares ⓘ	0	0	0	0	0	0	0	0	0	0
Net Proceeds from Borrowing ⓘ	-0.10	-0	0	0	0.29	10.14	-10.50	0	0	0
Interest Paid ⓘ	-0.01	-0	-0	0	0	0	-0.11	-0.04	-3.87	-5.29
Dividend Paid ⓘ	0	0	0	0	0	0	0	0	0	0
Others ⓘ	-0	0	0	0.08	0	0	0	0	57.61	1,083.69
Net Cash Flow ⓘ	0	0.15	-0.14	1.06	-0.15	-0.11	0.62	20.42	-20.33	-0.16

Financial Ratio

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Ratios
ROE (%)	0.36	0.11	0.45	0.26	8.62	13.33	24.51	70.92	122.76	3.55
ROCE (%)	0.66	0.14	0.55	0.62	11.16	7.39	18.16	102.54	99.51	1.76
Asset Turnover Ratio	0.76	0.34	0.11	0.05	0.74	4.21	3.85	0.74	2.61	0.13
PAT to CFO Conversion(x)	-136	N/A	-16	-7	-0.71	-21.27	10.44	3.78	-2.27	-704.99
Working Capital Days
Receivable Days	224.30	687.50	2,189.20	2,487.10	103.40	51.10	31.70	84.60	49.40	1,239.80
Inventory Days	100.50	0	0	469.60	57.20	7.70	31.50	32.60	6.40	330.20
Payable Days	0	0	0	1,426.40	80.60	50.30	54.30	77.20	36.30	872.60

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Supha Pharmachem Ltd FAQs

The current trading price of Supha Pharmachem on 11-Jun-2026 16:59 is ₹0.29.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 10-Jun-2026 the market cap of Supha Pharmachem stood at ₹26.46 Cr

The latest P/E ratio of Supha Pharmachem as of 10-Jun-2026 is 0.00.

The latest P/B ratio of Supha Pharmachem as of 10-Jun-2026 is 0.29.

The 52-week high of Supha Pharmachem is ₹1.80 and the 52-week low is ₹0.30.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Supha Pharmachem is ₹147 ( Cr.) .

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Supha Pharmachem Ltd is a below average quality company.

The key valuation ratios of Supha Pharmachem Ltd's currently when compared to its past seem to suggest it is in the Somewhat Undervalued zone.

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Supha Pharmachem Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

About Supha Pharmachem Ltd

Remedium Lifecare Ltd. (formerly known as Roxy Exports Limited) is a BSE listed company. The company has made a paradigm shift by entering into the manufacturing of intermediates and APIs and be reckoned as a leading contract manufacturer and as a brand owner of advanced intermediates & APIs. The strategic acquisition of the state-of-the-art manufacturing facilities in Hyderabad, was a timely move to forward integrate and diversify into the pharma & healthcare arena. A massive facility with 2 dedicated manufacturing blocks is now ready for large scale manufacture.

The company is engaged into the business of trading in API Intermediates (KSMs & CRMs) and various other raw materials used in API trading viz. Amino isophthalic Acid, Tellurium (IV) Oxide, Grignard Reagent, lodine, Selenium Metal Powder, Trimethyl Sulfoxonium lodide (TMSI).

Business area of the company

The company is pharmaceutical company aligned across two business verticals viz. Products and Services. Its Products business comprises manufacture and sale of APIs and Intermediates to innovator and generic pharmaceutical players in both Domestic and International markets including the regulated markets.

Supha Pharmachem Ltd (539561)

Supha Pharmachem Ltd (539561)

Supha Pharmachem stock performance

Check Before You Invest

M-Cap below 100cr DeciZen not available

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Value Creation ⓘ

Growth Parameters ⓘ

CAGR ⓘ

Key Financial Parameters ⓘ

Profit And Loss

Valuation of Supha Pharmachem - Standalone

Price Calculator

Price Chart

Price to Earnings

Price to Sales

Price to Book

EV to EBITDA

Dividend History

Analyst's Notes

Balance Sheet

Equity and Liabilities

Fixed Assets

Cash Flow

Financial Ratio

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Supha Pharmachem Ltd FAQs

About Supha Pharmachem Ltd

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Supha Pharmachem Ltd (539561)

Supha Pharmachem Ltd (539561)

Supha Pharmachem stock performance

Check Before You Invest

M-Cap below 100cr DeciZen not available

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Value Creation ⓘ

Growth Parameters ⓘ

CAGR ⓘ

Key Financial Parameters ⓘ

Profit And Loss

Valuation of Supha Pharmachem - Standalone

Price Calculator

Price Chart

Price to Earnings

Price to Sales

Price to Book

EV to EBITDA

Dividend History

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

Balance Sheet

Equity and Liabilities

Fixed Assets

Cash Flow

Financial Ratio

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Supha Pharmachem Ltd FAQs

What is the share price of Supha Pharmachem?

What is the market cap of Supha Pharmachem?

What is the P/E ratio of Supha Pharmachem?

What is the P/B ratio of Supha Pharmachem?

What is the 52-week high and low of Supha Pharmachem?

What is the TTM revenue of Supha Pharmachem?

Is Supha Pharmachem Ltd a good quality company?

Is Supha Pharmachem Ltd undervalued or overvalued?

Is Supha Pharmachem Ltd a good buy now?

About Supha Pharmachem Ltd

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.